Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-8364 tablets approved for clinical trials.
Hengrui Medicine (600276.SH) announcement, the company has received the approval and issuance of the National Medical Products Administration on HRS-...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company has received approval from the National Medical Products Administration to conduct clinical trials for HRS-8364 tablets. HRS-8364 is an innovative anti-tumor drug developed independently by the company, intended for the treatment of advanced solid tumors.
Related Articles
CF PHARMTECH (02652): Recommended to fully implement H-share circulation.
ZTO EXPRESS-W(02057) releases "Double Eleven" battle report: "Hexagon" ZTO, serving more merchants to win the peak season steadily.
Shenwan Hongyuan Group (06806): Shenwan Hongyuan Group Securities completes the issuance of 4.5 billion yuan corporate bonds.
CF PHARMTECH (02652): Recommended to fully implement H-share circulation.
ZTO EXPRESS-W(02057) releases "Double Eleven" battle report: "Hexagon" ZTO, serving more merchants to win the peak season steadily.
Shenwan Hongyuan Group (06806): Shenwan Hongyuan Group Securities completes the issuance of 4.5 billion yuan corporate bonds.
